Corvus Pharmaceuticals (CRVS) Net Cash Flow (2015 - 2026)

Corvus Pharmaceuticals' Net Cash Flow history runs 12 years deep, the most recent figure standing at $35.5 million for Q1 2026.

• In Q1 2026, Net Cash Flow rose 1049.64% year-over-year to $35.5 million; the TTM figure through Mar 2026 stood at $35.1 million (up 206.93% YoY), while the FY2025 annual figure was -$4.2 million, down 7.32% from the prior year.
• Net Cash Flow was $35.5 million for Q1 2026 at Corvus Pharmaceuticals, up from $1.7 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $35.5 million in Q1 2026 to a low of -$32.0 million in Q1 2022.
• Historically, Net Cash Flow has averaged -$3.2 million across 5 years, with a median of -$3.7 million in 2025.
• The sharpest annual moves came in 2024 and 2026: Net Cash Flow tumbled 1051.55% in 2024, then soared 1049.64% in 2026.
• A 5-year view of Net Cash Flow shows it stood at -$11.4 million in 2022, then jumped by 34.51% to -$7.5 million in 2023, then jumped by 154.24% to $4.1 million in 2024, then tumbled by 57.91% to $1.7 million in 2025, then surged by 1978.76% to $35.5 million in 2026.
• The last three Net Cash Flow figures came in at $35.5 million (Q1 2026), $1.7 million (Q4 2025), and -$11.8 million (Q3 2025), per Business Quant data.